EP3801378A4 - Implantable device for sustained release of a macromolecular drug compound - Google Patents

Implantable device for sustained release of a macromolecular drug compound Download PDF

Info

Publication number
EP3801378A4
EP3801378A4 EP19806736.5A EP19806736A EP3801378A4 EP 3801378 A4 EP3801378 A4 EP 3801378A4 EP 19806736 A EP19806736 A EP 19806736A EP 3801378 A4 EP3801378 A4 EP 3801378A4
Authority
EP
European Patent Office
Prior art keywords
sustained release
implantable device
drug compound
macromolecular drug
macromolecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19806736.5A
Other languages
German (de)
French (fr)
Other versions
EP3801378A1 (en
Inventor
Christian Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celanese EVA Performance Polymers LLC
Original Assignee
Celanese EVA Performance Polymers LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celanese EVA Performance Polymers LLC filed Critical Celanese EVA Performance Polymers LLC
Publication of EP3801378A1 publication Critical patent/EP3801378A1/en
Publication of EP3801378A4 publication Critical patent/EP3801378A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0069—Devices for implanting pellets, e.g. markers or solid medicaments
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22032—Stem bromelain (3.4.22.32)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22033—Fruit bromelain (3.4.22.33), i.e. juice bromelain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19806736.5A 2018-05-24 2019-05-20 Implantable device for sustained release of a macromolecular drug compound Pending EP3801378A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862675994P 2018-05-24 2018-05-24
PCT/US2019/033063 WO2019226519A1 (en) 2018-05-24 2019-05-20 Implantable device for sustained release of a macromolecular drug compound

Publications (2)

Publication Number Publication Date
EP3801378A1 EP3801378A1 (en) 2021-04-14
EP3801378A4 true EP3801378A4 (en) 2022-02-23

Family

ID=68615401

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19806736.5A Pending EP3801378A4 (en) 2018-05-24 2019-05-20 Implantable device for sustained release of a macromolecular drug compound

Country Status (11)

Country Link
US (1) US11690806B2 (en)
EP (1) EP3801378A4 (en)
JP (2) JP2021524840A (en)
KR (1) KR20210013089A (en)
CN (1) CN111989068A (en)
AU (1) AU2019275409A1 (en)
BR (1) BR112020023982A2 (en)
CA (1) CA3087410A1 (en)
MX (1) MX2020012459A (en)
SG (1) SG11202005949UA (en)
WO (1) WO2019226519A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019226516A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
US20220313725A1 (en) * 2021-03-30 2022-10-06 Celanese Eva Performance Polymers Llc Implantable Medical Device for the Delivery of a Nucleic Acid
CA3230804A1 (en) * 2021-09-22 2023-03-30 Vijay GYANANI Refillable implantable device for delivering a drug compound
US20230233375A1 (en) * 2022-01-24 2023-07-27 Celanese Eva Performance Polymers Llc Implantable Device for Delivery of a Tyrosine Kinase Inhibitor
WO2023163914A1 (en) * 2022-02-22 2023-08-31 Celanese Eva Performance Polymers Llc Intravaginal ring device for the delivery of aromatase inhibitor
US20230364009A1 (en) * 2022-05-12 2023-11-16 Celanese Eva Performance Polymers Llc Implantable Medical Device for the Delivery of an Antipsychotic
US20230404907A1 (en) * 2022-06-13 2023-12-21 Celanese Eva Performance Polymers Llc Monolithic Implantable Device for Sustained Release of an Antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090035381A1 (en) * 2007-08-01 2009-02-05 Stankus John J Electrospraying method for fabrication of particles and coatings and treatment methods thereof
US9175162B2 (en) * 2003-05-08 2015-11-03 Advanced Cardiovascular Systems, Inc. Methods for forming stent coatings comprising hydrophilic additives

Family Cites Families (287)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4391797A (en) 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4164560A (en) 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
US4357312A (en) 1981-07-16 1982-11-02 The Children's Hospital Medical Center Method of making prolonged release body
US4891225A (en) 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4863735A (en) 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US4900556A (en) 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4666704A (en) 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
US4952406A (en) 1985-06-27 1990-08-28 The Children's Medical Center Corporation Feedback controlled release
US4663147A (en) 1985-09-03 1987-05-05 International Minerals & Chemical Corp. Disc-like sustained release formulation
US5008112A (en) 1985-12-16 1991-04-16 International Minerals & Chem. Corporation Device for the extended delivery of diffusible agents
US4933185A (en) 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5601835A (en) 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
US4792448A (en) 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
ATE86484T1 (en) * 1987-08-08 1993-03-15 Akzo Nv CONTRACEPTIVE IMPLANT.
US4898734A (en) 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
US5100668A (en) 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
US5356630A (en) 1989-02-22 1994-10-18 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
US5439688A (en) 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
US4989734A (en) 1990-05-29 1991-02-05 Mode Ronald L Order filler and supply container apparatus
HU208495B (en) 1990-06-27 1993-11-29 Alkaloida Vegyeszeti Gyar Process for producing retarde pharmaceutical compositions
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5340581A (en) 1991-08-23 1994-08-23 Gillette Canada, Inc. Sustained-release matrices for dental application
US5302397A (en) 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
US5512293A (en) 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5543465A (en) 1993-03-19 1996-08-06 Gambro Dialysatoren Gmbh & Co. Process for the production of hydrophilic membranes
CA2176145C (en) 1993-11-15 2007-04-10 Vernon G. Wong Biocompatible ocular implants
WO1995024929A2 (en) * 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
US8795242B2 (en) 1994-05-13 2014-08-05 Kensey Nash Corporation Resorbable polymeric device for localized drug delivery
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
AUPM897594A0 (en) 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
DE4441575C2 (en) 1994-11-22 1998-08-06 Bruker Analytische Messtechnik Device and method for quickly discharging a superconducting magnet coil
US6281015B1 (en) 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
DE69616551T2 (en) 1995-07-04 2002-05-29 Akzo Nobel Nv RING-SHAPED DEVICE
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
CA2184316A1 (en) 1995-09-12 1997-03-13 Wei-Chi Liao Buccal delivery system for therapeutic agents
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6586401B1 (en) 1996-02-16 2003-07-01 Children's Medical Center Corporation Troponin subunit I fragment and homologs thereof
US5733565A (en) 1996-02-23 1998-03-31 The Population Council, Center For Biomedical Research Male contraceptive implant
AU765149B2 (en) 1996-04-08 2003-09-11 New York University Medical Center Method for gene transfer to the central nervous system
US6210664B1 (en) 1996-04-08 2001-04-03 New York University Medical Center Method for gene transfer to the central nervous system
ATE359805T1 (en) 1996-08-30 2007-05-15 Peptech Ltd SUSTAINED RELEASE FORMULATION OF GNRH PEPTIDE AGONISTS AND ANALOGS
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
JP3966481B2 (en) 1997-02-18 2007-08-29 東レ株式会社 Semipermeable membrane
TW358031B (en) 1997-04-11 1999-05-11 Akze Nobel N V Drug delivery system for 2 or more active substances
US10028851B2 (en) 1997-04-15 2018-07-24 Advanced Cardiovascular Systems, Inc. Coatings for controlling erosion of a substrate of an implantable medical device
WO1999009149A1 (en) 1997-08-01 1999-02-25 Massachusetts Institute Of Technology Three-dimensional polymer matrices
US6096764A (en) 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
WO1999034834A1 (en) 1998-01-02 1999-07-15 Titan Pharmaceuticals, Inc. Use of pigmented retinal epithelial cells for creation of an immune privilege site
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
US20020188037A1 (en) 1999-04-15 2002-12-12 Chudzik Stephen J. Method and system for providing bioactive agent release coating
JP3406903B2 (en) 1998-04-27 2003-05-19 サーモディックス，インコーポレイティド Coating releasing bioactive agent
US6730322B1 (en) 1998-04-30 2004-05-04 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6423345B2 (en) 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6159143A (en) 1998-06-17 2000-12-12 Scimed Life Systems, Inc. Method and device for delivery of therapeutic agents in conjunction with isotope seed placement
US6117441A (en) 1998-07-02 2000-09-12 The Population Council, Inc. Silicone core long term androgen delivery implant
JP2002524108A (en) 1998-07-28 2002-08-06 インナーダイン， インコーポレイテッド Absorbable brachytherapy and chemotherapy delivery devices and methods
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20040121014A1 (en) 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US7115256B1 (en) 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6767550B1 (en) 2000-06-30 2004-07-27 Berkeley Advanced Biomaterials, Inc. Hydroxyapatite based drug delivery implant for cancer treatment
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6719750B2 (en) 2000-08-30 2004-04-13 The Johns Hopkins University Devices for intraocular drug delivery
US7666445B2 (en) 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
KR20030045847A (en) 2000-10-31 2003-06-11 쿡 인코포레이티드 Coated implantable medical device
WO2002053129A1 (en) 2001-01-03 2002-07-11 Bausch & Lomb Incorporated Sustained release drug delivery devices with prefabricated permeable plugs
CA2433528A1 (en) 2001-01-26 2002-08-01 Bausch & Lomb Incorporated Improved process for the production of sustained release drug delivery devices
GB0104383D0 (en) 2001-02-22 2001-04-11 Psimedica Ltd Cancer Treatment
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
WO2002087616A1 (en) 2001-04-25 2002-11-07 Takeda Chemical Industries, Ltd. Preventives for postoperative recurrence of premenopausal breast cancer
US20040022853A1 (en) 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
CA2451187C (en) * 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
AUPR602401A0 (en) 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
JP2003137814A (en) 2001-08-10 2003-05-14 Takeda Chem Ind Ltd COMBINED PHARMACEUTICAL OF GnRH AGONIST
US7195774B2 (en) 2001-08-29 2007-03-27 Carvalho Ricardo Azevedo Ponte Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues
US7989018B2 (en) * 2001-09-17 2011-08-02 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US20030149008A1 (en) 2002-02-07 2003-08-07 Velayudhan Sahadevan Hormonal implants treatment of the breast cancer
US8685427B2 (en) 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
DE10208344A1 (en) 2002-02-27 2003-09-04 Roehm Gmbh Melt extrusion of active ingredient salts
US20030203000A1 (en) 2002-04-24 2003-10-30 Schwarz Marlene C. Modulation of therapeutic agent release from a polymeric carrier using solvent-based techniques
WO2003092665A2 (en) 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
PT2561860T (en) 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of buprenorphine
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
ZA200500418B (en) 2002-07-17 2006-10-25 Titan Pharmaceuticals Inc Combination of chemotherapeutic drugs for increasing anitumor activity
DE10250543A1 (en) 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Multilayer dosage form
US7189461B2 (en) * 2003-03-04 2007-03-13 Air Products Polymers, L.P. Semi-crystalline ethylene vinyl acetate emulsion polymers for heat seal applications
EP1610791B1 (en) 2003-03-31 2011-02-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
DE602004026173D1 (en) 2003-04-29 2010-05-06 Gen Hospital Corp METHOD AND DEVICES FOR THE DELAYED RELEASE OF SEVERAL MEDICAMENTS
AU2004237774B2 (en) 2003-05-02 2009-09-10 Surmodics, Inc. Implantable controlled release bioactive agent delivery device
US20040224000A1 (en) 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
TWI336627B (en) 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
MXPA05012768A (en) 2003-05-30 2006-02-22 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of nalmefene.
DE10332160A1 (en) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multiparticulate dosage form containing mucoadhesively formulated peptide or protein active substances, and a method for producing the dosage form
US20050159676A1 (en) 2003-08-13 2005-07-21 Taylor James D. Targeted biopsy delivery system
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
CA2448995A1 (en) 2003-11-12 2005-05-12 James Keenan Device and method for attracting diseased cells and foreign substances
CA2550119A1 (en) 2003-12-17 2005-06-30 Titan Pharmaceuticals, Inc. Use of gallium to treat inflammatory arthritis
US20060003008A1 (en) 2003-12-30 2006-01-05 Gibson John W Polymeric devices for controlled release of active agents
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US7803178B2 (en) 2004-01-30 2010-09-28 Trivascular, Inc. Inflatable porous implants and methods for drug delivery
WO2005087221A1 (en) 2004-03-15 2005-09-22 Christine Allen Biodegradable biocompatible implant and method of manufacturing same
TWI434676B (en) 2004-03-19 2014-04-21 Merck Sharp & Dohme X-ray visible drug delivery device
CA2559224C (en) 2004-03-24 2011-12-13 N.V. Organon Drug delivery system based on polyethylene vinylacetate copolymers
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244462A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US20060110428A1 (en) 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
DE102004036437A1 (en) 2004-07-27 2006-03-23 Röhm GmbH & Co. KG Multiparticulate dosage form for sparingly soluble active ingredients, as well as a method for producing the dosage form
WO2006078320A2 (en) 2004-08-04 2006-07-27 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US7594899B2 (en) 2004-12-03 2009-09-29 Innfocus, Llc Glaucoma implant device
WO2006063242A1 (en) 2004-12-10 2006-06-15 Titan Pharmaceuticals, Inc. Methods and compositions for induction of tumor regression
DE102004059792A1 (en) 2004-12-10 2006-06-14 Röhm GmbH & Co. KG Multiparticulate dosage form containing mucoadhesively formulated nucleic acid active ingredients, and a method for producing the dosage form
US20060127463A1 (en) 2004-12-15 2006-06-15 Nugara Peter N Composite structure including a low vinyl acetate layer
JP2008524235A (en) 2004-12-15 2008-07-10 キューエルティー ユーエスエー，インコーポレイテッド． Sustained release delivery formulation for octreotide compounds
US20060188543A1 (en) 2005-01-31 2006-08-24 Si-Shen Feng Nanoparticle coating for drug delivery
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
US7531503B2 (en) 2005-03-11 2009-05-12 Wake Forest University Health Sciences Cell scaffold matrices with incorporated therapeutic agents
US8298565B2 (en) 2005-07-15 2012-10-30 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US8858993B2 (en) 2005-07-25 2014-10-14 Metrics, Inc. Coated tablet with zero-order or near zero-order release kinetics
EP1933810B1 (en) 2005-08-11 2012-10-10 Massachusetts Institute of Technology Intravesical drug delivery device and method
CN101287507B (en) 2005-08-12 2012-12-05 刘江 Methods and devices for lymphatic targeting
US20070212397A1 (en) 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
KR100648519B1 (en) 2005-10-21 2006-11-27 주식회사 컴테크케미칼 Ethylene vinyl acetate based polymer foams with low density and injection preparation method thereof
US20070128294A1 (en) 2005-11-07 2007-06-07 Bucalo Louis R Treatment and prevention of liver adverse conditions using gallium
EP1957113A4 (en) 2005-11-21 2011-11-09 Medivas Llc Polymer particles for delivery of macromolecules and methods of use
US10029034B2 (en) 2005-12-15 2018-07-24 CARDINAL HEALTH SWITZERLAND 515 GmbH Drug-eluting articles with improved drug release profiles
CN101385698A (en) 2005-12-20 2009-03-18 济南康泉医药科技有限公司 Anti-cancer sustained-released implantation agent
US20070231406A1 (en) 2006-01-30 2007-10-04 Bucalo Louis R Use of gallium to treat biofilm-associated infections
PL1978936T3 (en) 2006-02-03 2013-11-29 Evonik Roehm Gmbh Pharmaceutical compositions containing mixtures of polymers and active agents poorly soluble in water
WO2007112946A1 (en) 2006-03-30 2007-10-11 Universite De Geneve Intraocular lens with drug delivery system attached thereto
US20070260203A1 (en) 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
DE102006035549A1 (en) 2006-07-27 2008-01-31 Evonik Röhm Gmbh Pharmaceutical form with at least two-layer separating layer
SI2051704T1 (en) 2006-08-18 2012-08-31 Evonik Roehm Gmbh Pharmaceutical composition with controlled active ingredient delivery for active ingredients with good solubility in water
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
EP2094348A1 (en) 2006-11-22 2009-09-02 N.V. Organon Delivery system for a non-steroidal non-ionized hydrophilic drug
US20080145406A1 (en) 2006-12-18 2008-06-19 Alcon Manufacturing Ltd. Devices and methods for ophthalmic drug delivery
HUE026001T2 (en) 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
CN101011345A (en) 2007-02-12 2007-08-08 济南帅华医药科技有限公司 Slow release injection containing platinum compound and alkylating agent
WO2008106213A1 (en) 2007-02-27 2008-09-04 Titan Pharmaceuticals, Inc. Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome.
ES2562878T3 (en) 2007-05-25 2016-03-08 Indivior Uk Limited Sustained release formulations of risperidone compounds
CN105581976A (en) 2007-06-26 2016-05-18 沃纳奇尔科特有限责任公司 Intravaginal drug delivery devices for the delivery of macromolecules and watersoluble drugs
NZ598483A (en) 2007-09-07 2013-08-30 Quadra Logic Tech Inc Drug cores for sustained release of therapeutic agents
TW200930343A (en) 2007-09-21 2009-07-16 Organon Nv Drug delivery system
WO2009051819A1 (en) 2007-10-17 2009-04-23 Axxia Pharmaceuticals, Llc Polymeric drug delivery systems and thermoplastic extrusion processes for producing such systems
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
WO2009094573A2 (en) 2008-01-25 2009-07-30 The University Of Utah Research Foundation Linear order release polymer
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
EP2254602B1 (en) 2008-02-13 2018-11-21 President and Fellows of Harvard College Continuous cell programming devices
EP2254857A4 (en) 2008-02-21 2014-06-25 Univ Rutgers Compositions and methods for treating ophthalmic diseases
WO2009129459A1 (en) 2008-04-18 2009-10-22 Combinent Biomedical Systems, Inc. Devices that include ethylene-vinyl acetate copolymers and methods of making and using same
US8496954B2 (en) 2008-04-18 2013-07-30 Surmodics, Inc. Coating systems for the controlled delivery of hydrophilic bioactive agents
CN102105137B (en) 2008-04-30 2015-01-07 Qlt股份有限公司 Composite lacrimal insert and related methods
US8795707B2 (en) 2008-05-13 2014-08-05 Trustees Of Boston University Compliant composites for application of drug-eluting coatings to tissue surfaces
DE102008002395A1 (en) 2008-06-12 2009-12-17 Biotronik Vi Patent Ag Drug-loaded implant
US8071537B2 (en) 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
WO2010033771A2 (en) 2008-09-19 2010-03-25 Trustees Of The University Of Pennsylvania Modulators of hsp70/dnak function and methods of use thereof
JP2012504146A (en) 2008-09-30 2012-02-16 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． Implantable device for delivery of risperidone and method of use thereof
US20110280922A1 (en) 2008-11-07 2011-11-17 Combinent Biomedical Systems, Inc. Devices and methods for treating and/or preventing diseases
MX2011005272A (en) 2008-11-20 2011-06-21 Insight Innovations Llc Biocompatible biodegradable intraocular implant system.
US20100158980A1 (en) 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
DK2381932T3 (en) 2009-01-29 2018-11-19 Fondazione Irccs Istituto Naz Dei Tumori INTRACERVIC DEVICE FOR THE RELEASE OF PHARMACEUTICALS IN THE LOCAL-REGIONAL TREATMENT OF CANCER CANCER
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
TW201034641A (en) 2009-02-28 2010-10-01 Charles Knezevich Apparatus, system, and method for creating immunologically enhanced spaces in-vivo
US9345686B2 (en) 2009-03-17 2016-05-24 Intervet Inc. Macrocyclic lactone drug delivery system
CA2979355C (en) 2009-05-18 2023-02-21 Dose Medical Corporation Drug eluting ocular implant
FI20095550A0 (en) 2009-05-19 2009-05-19 Bayer Schering Pharma Oy Vaginal delivery system
FI20095563A (en) 2009-05-20 2010-11-21 Bayer Schering Pharma Oy Vaginal delivery system
CA2767168C (en) 2009-07-08 2019-04-09 Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
AU2010272167B2 (en) 2009-07-14 2016-11-17 Polypid Ltd. Sustained-release drug carrier composition
CN102497855B (en) 2009-07-21 2013-12-25 人口委员会股份有限公司 Multi-layered gradient vaginal ring
US20110038936A1 (en) 2009-08-17 2011-02-17 Kimberly Ann Griswold System and method for electrospun drug loaded biodegradable chemotherapy applications
US20110105990A1 (en) 2009-11-04 2011-05-05 Silvestrini Thomas A Zonal drug delivery device and method
US8911426B2 (en) 2010-02-08 2014-12-16 On Demand Therapeutics, Inc. Low-permeability, laser-activated drug delivery device
KR101708086B1 (en) 2010-02-25 2017-02-17 에보니크 룀 게엠베하 Pharmaceutical or neutraceutical formulation
SG10201501964QA (en) 2010-03-16 2015-05-28 Titan Pharmaceuticals Inc Heterogeneous Implantable Devices For Drug Delivery
US20130273137A1 (en) 2010-05-03 2013-10-17 Massachusetts Eye & Ear Infirmary Drug delivery coating and devices
JP2013526572A (en) 2010-05-17 2013-06-24 アエリエ・ファーマシューティカルズ・インコーポレーテッド Drug delivery device for the delivery of eye treatments
US8747883B2 (en) 2010-06-02 2014-06-10 Princeton Trade & Technology, Inc. Medical item for long term drug release
US8236857B2 (en) 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120029042A1 (en) 2010-07-30 2012-02-02 Warsaw Orthopedic, Inc. Clonidine for treatment of bone cancer
SG187786A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A biodegradable ocular implant
US9370444B2 (en) 2010-10-12 2016-06-21 Emmett T. Cunningham, JR. Subconjunctival conformer device and uses thereof
US8900616B2 (en) 2010-10-22 2014-12-02 Covidien Lp System and method for satellite drug delivery
US20130287688A1 (en) 2010-11-18 2013-10-31 Xtuit Pharmaceuticals, Inc. Novel compositions and uses of anti-hypertension agents for cancer therapy
US8911427B2 (en) * 2010-12-28 2014-12-16 Medtronic, Inc. Therapeutic agent reservoir delivery system
CA2827082A1 (en) 2011-02-11 2012-08-16 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics
WO2012142328A2 (en) 2011-04-12 2012-10-18 Ratner Buddy D Polymer microsphere compositions for localized delivery of therapeutic agents
US20120277719A1 (en) 2011-04-27 2012-11-01 Massachusetts Institute Of Technology Coating compositions, methods and coated devices
LT2529756T (en) 2011-05-31 2021-07-26 Laboratorios Farmaceuticos Rovi, S.A. Risperidone and/or paliperidone implant formulation
ES2456917T3 (en) 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Paliperidone implant formulation
MX353427B (en) 2011-06-17 2018-01-12 Evonik Roehm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms.
MX356579B (en) 2011-06-17 2018-06-05 Evonik Roehm Gmbh Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol.
AU2011370763A1 (en) 2011-06-17 2013-10-03 Evonik Rohm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms
WO2012177968A1 (en) 2011-06-22 2012-12-27 The Schepens Eye Research Institute, Inc. A scaffold for subretinal cell transplantation and drug delivery
KR20140074281A (en) 2011-07-20 2014-06-17 패트릭 에프. 카이저 Intravaginal devices for drug delivery
US20140314966A1 (en) 2011-10-05 2014-10-23 Applied Nanotech Holdings, Inc. Sintering Metallic Inks on Low Melting Point Substrates
TWI583401B (en) 2011-10-24 2017-05-21 布雷本製藥股份有限公司 Implantable tizanidine compositions and methods of treatment thereof
EP2591770B1 (en) 2011-11-14 2016-03-16 Silenseed Ltd Compositions for siRNA delivery and methods of manufacturing and using same
AU2012351886A1 (en) 2011-12-16 2014-07-31 Combinent Biomedical Systems, Inc. Vaginal drug delivery devices and manufacturing methods
WO2013090893A1 (en) 2011-12-16 2013-06-20 Celanese Eva Performance Polymers, Inc. Gastroretentive controlled release vehicles that include ethylene copolymers, ethyl celluloses, and/or thermpoplastic polyurethanes
TW201332585A (en) 2012-02-14 2013-08-16 Chemo Res S L Core sheath drug delivery devices
WO2013124869A2 (en) 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University The art, method,manner process and system of fibrous bio-degradable polymeric wafers for the local delivery of therapeutic agents in combinations
DE102013011399A1 (en) 2012-07-31 2014-02-06 Amw Gmbh Rod-shaped biodegradable implant useful for maintenance therapy in schizophrenia in patients comprises risperidone
SI2887925T1 (en) 2012-08-27 2017-06-30 Evonik Roehm Gmbh Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
ES2600860T3 (en) 2012-08-27 2017-02-13 Evonik Röhm Gmbh Pharmaceutical or nutraceutical composition with delayed release characteristic and with resistance against the influence of ethanol
EP2708213A1 (en) 2012-09-13 2014-03-19 PAT&Co bvba Multipurpose ethylene vinyl acetate fibrous drug delivery systems for long-term implantation or insertion
JP6317748B2 (en) 2012-09-27 2018-04-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Biodegradable drug delivery system for sustained protein release
US20140128349A1 (en) 2012-11-02 2014-05-08 Indiana University School of Medicine Administering inhibitors of tgfbeta signaling in combination with benzothiazepine derivatives to improve muscle function in cancer patients
WO2014078832A1 (en) 2012-11-19 2014-05-22 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
CA2886650A1 (en) 2012-11-29 2014-06-05 The Penn State Research Foundation Photodynamic dhsip anticancer therapeutic and immunomodulator
US20160008399A1 (en) 2013-01-14 2016-01-14 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
US20140212355A1 (en) 2013-01-28 2014-07-31 Abbott Cardiovascular Systems Inc. Trans-arterial drug delivery
BR112015018895A2 (en) 2013-02-13 2017-07-18 Evonik Roehm Gmbh multiparticulate pharmaceutical composition comprising a multiplicity of two types of pellets
JP6511401B2 (en) 2013-02-15 2019-05-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Sustained drug delivery implant
US20160022571A1 (en) 2013-03-14 2016-01-28 Braeburn Pharmaceuticals Bvba Sprl Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
WO2014160026A2 (en) 2013-03-14 2014-10-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions comprising sugar-based sorption enhancers and methods of treatment thereof
US20140271765A1 (en) 2013-03-15 2014-09-18 Titan Pharmaceuticals, Inc. Methods and device for treating opioid addiction
MX2015013457A (en) 2013-03-21 2016-05-16 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith.
WO2014169137A1 (en) 2013-04-10 2014-10-16 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
US20160067071A1 (en) 2013-04-24 2016-03-10 Trustees Of Tufts College Bioresorbable biopolymer stent
WO2014179568A2 (en) 2013-05-02 2014-11-06 Odin Biotech Two-layer ocular implant
WO2014180516A1 (en) 2013-05-09 2014-11-13 Evonik Röhm Gmbh Process for stabilizing the drug release profiles of polymer film coated pharmaceutical compositions
EA032465B1 (en) 2013-07-12 2019-05-31 Грюненталь Гмбх Tamper-resistant oral pharmaceutical dosage form containing ethylene-vinyl acetate polymer and process for the production thereof
WO2015013716A1 (en) 2013-07-26 2015-01-29 The Regents Of The University Of California Patient-specific temporary implants for accurately guiding local means of tumor control along patient-specific internal channels to treat cancers
CN103435424B (en) 2013-09-02 2016-03-30 济宁道淼新材料科技有限公司 A kind of slow controlled release coated fertilizer of the pbz polymer micro-nano grain of rice
EP3068372B1 (en) 2013-11-14 2019-05-08 EyeD Pharma Eye device
KR20220082934A (en) 2013-11-15 2022-06-17 알레간 인코포레이티드 Methods of treatment of ocular conditions with a sustained drug delivery implant
US20160302965A1 (en) 2013-12-06 2016-10-20 Forsight Vision4, Inc. Implantable therapeutic devices
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
US10596103B2 (en) 2013-12-11 2020-03-24 Merek Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US9895318B2 (en) 2014-02-17 2018-02-20 Evonik Roehm Gmbh Pharmaceutical or nutraceutical composition with sustained release characteristic and with resistance against the influence of ethanol
US20150307754A1 (en) 2014-04-28 2015-10-29 Celanese Acetate Llc Adhesives that include highly-plasticized cellulose esters and methods and articles relating thereto
JP7348708B2 (en) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Combination vaccine device and method for killing cancer cells
JP2017522365A (en) 2014-05-30 2017-08-10 テクスタイル−ベイスド デリバリー，インコーポレイテッド Drug delivery system and related methods of use
TWI522099B (en) 2014-06-04 2016-02-21 中國醫藥大學 Pharmaceutical formulation for treating pancreatic cancer and uses of the same
CN111214701A (en) 2014-08-19 2020-06-02 加利福尼亚大学董事会 Implants for localized drug delivery and methods of use thereof
US10226419B2 (en) * 2014-09-08 2019-03-12 ProMed Pharma, LLC Methods for manufacturing implants
MX2017003638A (en) 2014-09-19 2017-11-08 Eupraxia Pharmaceuticals Inc Injectable microparticles for hyper-localized release of therapeutic agents.
WO2016064959A1 (en) 2014-10-21 2016-04-28 Odin Biotech Two-layer ocular implant comprising a tyrosine kinase inhibitor
FR3028410A1 (en) 2014-11-18 2016-05-20 Pierre Coulon MULTIFUNCTIONAL CAPSULAR IMPLANT
JP6695337B2 (en) 2014-11-26 2020-05-20 レーム・ゲーエムベーハーＲｏｅｈｍ ＧｍｂＨ Pharmaceutical composition or nutraceutical composition having resistance to the influence of ethanol
EP3294300A1 (en) 2015-05-13 2018-03-21 Bayer Oy A long acting drug delivery device and its use in contraception
US20180125780A1 (en) 2015-05-15 2018-05-10 The Methodist Hospital System Implantable nanochannel delivery devices
WO2016187355A1 (en) 2015-05-20 2016-11-24 Glaukos Corporation Therapeutic drug compositions and implants for delivery of same
SI3302444T1 (en) 2015-06-05 2021-01-29 Evonik Operations Gmbh Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
CN117442742A (en) 2015-06-18 2024-01-26 灵敏生物公司 Implantable drug delivery compositions and methods of use thereof
WO2017019829A1 (en) 2015-07-28 2017-02-02 Board Of Regents, The University Of Texas System Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
EP3334460A4 (en) 2015-08-13 2019-04-03 Northeastern University Biomaterials for combined radiotherapy and immunotherapy of cancer
WO2017040855A1 (en) 2015-09-02 2017-03-09 Dose Medical Corporation Drug delivery implants as intraocular drug depots and methods of using same
US9896576B2 (en) 2015-10-29 2018-02-20 Celanese EVA Performance Polymers Corporation Medical tube
PT109154B (en) 2016-02-12 2019-11-05 Univ De Coimbra NON-INVASIVE EYE INSERT TECHNOLOGY FOR CONTROLLED DRUG RELEASE
CN109477085B (en) 2016-04-22 2023-08-01 萨鲁德医疗公司 Methods and compositions for enhancing anti-inflammatory effects of interleukin 10
WO2017210668A1 (en) 2016-06-03 2017-12-07 Jt Pharmaceuticals, Inc. Sustained release compositions of kappa-opioid receptor agonist
WO2017214442A1 (en) 2016-06-08 2017-12-14 President And Fellows Of Harvard College Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome
JP7240311B2 (en) 2016-08-30 2023-03-15 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Drug delivery compositions and uses thereof
MX2019003804A (en) 2016-10-05 2019-08-05 Titan Pharmaceuticals Inc Implantable devices for drug delivery with reduced burst release.
AU2017377659A1 (en) 2016-12-13 2019-07-11 Beta Therapeutics Pty. Ltd. Methods of treating ocular disorders
US20200000976A1 (en) 2016-12-16 2020-01-02 Field Orthopaedics Pty Ltd A medical implant and a method of coating a medical implant
US10874768B2 (en) 2017-01-20 2020-12-29 Covidien Lp Drug eluting medical device
AU2018217064A1 (en) 2017-01-31 2019-08-08 Veru Inc. Compositions and methods for long term release of Gonadotropin-releasing hormone (GnRH) antagonists
EP3773478A1 (en) 2018-04-04 2021-02-17 Alivio Therapeutics, Inc. Self-assembled gels for controlled delivery of biologics and methods of making thereof
US11946064B2 (en) 2018-04-30 2024-04-02 The Brigham And Women's Hospital, Inc. Compositions and therapeutic methods of microRNA gene delivery
WO2019226516A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
CA3104513A1 (en) 2018-06-25 2020-01-02 Titan Pharmaceuticals, Inc. Implants for release of lipophilic or amphiphilic pharmaceutical substances
JP2021528452A (en) 2018-06-25 2021-10-21 タイタン ファーマシューティカルズ インコーポレイテッド Loadable porous structure for use as an implant
EP3813903A4 (en) 2018-06-29 2022-03-30 The Johns Hopkins University Magnetic resonance imaging compatible, convection-enhanced delivery cranial implant devices and related methods
US20210315980A1 (en) 2018-08-21 2021-10-14 Georgia State University Research Foundation, Inc. Treatment of flavivirus infections in humans using mus musculus resistant 2'-5' oligoadenylate synthetase 1b
WO2020077039A1 (en) 2018-10-12 2020-04-16 Synergene Therapeutics, Inc. Methods for reducing side effects of immunotherapy
JP2022527917A (en) 2019-03-28 2022-06-07 ザ ジェネラル ホスピタル コーポレイション Manipulated adeno-associated (AAV) vector for transgene expression
KR102264231B1 (en) 2019-07-19 2021-06-11 울산과학기술원 Biopolymers and metal-organic frameworks conjugated complexes and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9175162B2 (en) * 2003-05-08 2015-11-03 Advanced Cardiovascular Systems, Inc. Methods for forming stent coatings comprising hydrophilic additives
US20090035381A1 (en) * 2007-08-01 2009-02-05 Stankus John J Electrospraying method for fabrication of particles and coatings and treatment methods thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019226519A1 *

Also Published As

Publication number Publication date
US20190358166A1 (en) 2019-11-28
BR112020023982A2 (en) 2021-02-23
WO2019226519A1 (en) 2019-11-28
EP3801378A1 (en) 2021-04-14
CN111989068A (en) 2020-11-24
JP2021524840A (en) 2021-09-16
US11690806B2 (en) 2023-07-04
JP2024028832A (en) 2024-03-05
CA3087410A1 (en) 2019-11-28
MX2020012459A (en) 2021-04-28
KR20210013089A (en) 2021-02-03
SG11202005949UA (en) 2020-07-29
AU2019275409A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
EP3801462A4 (en) Implantable device for sustained release of a macromolecular drug compound
EP3801378A4 (en) Implantable device for sustained release of a macromolecular drug compound
EP3522825A4 (en) Implantable devices for drug delivery with reduced burst release
EP4149587A4 (en) Unidirectional-driven drug infusion device
EP4003458A4 (en) Unilateral-driven drug infusion device
EP3730152A4 (en) Combination drug including tlr7 agonist
EP3826589A4 (en) Ophthalmic device for drug delivery
EP3566686A4 (en) Drug feeder
EP3641855A4 (en) Time delay mechanism for a hydraulic drug delivery device
EP3967359A4 (en) Iontophoresis administration device
EP3638206A4 (en) Bioerodible drug delivery devices
EP3664885A4 (en) Transdermal drug delivery system
EP3664867A4 (en) Communication accessory for a drug delivery device
EP3212170A4 (en) Implantable medical devices for extended release of therapeutic agents
EP3643353A4 (en) Drug delivery robot
EP3703770A4 (en) A levelling device for positioning of a medical device
EP3761961A4 (en) Aqueous formulations for insoluble drugs
EP4043014A4 (en) Pharmaceutical drug containing heterocyclidene acetamide derivative
EP3687560A4 (en) Composition and method for controlled drug release from a tissue
EP3777893A4 (en) Use of bis-iminobiotin compound for drug delivery purposes
EP3735186A4 (en) A medical fastening device
EP3661576A4 (en) Medical nebulizer for fast drug delivery
EP4049698A4 (en) Drug delivery device
EP3590513A4 (en) Medical drug
EP4062938A4 (en) Combination drug

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220120

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 31/16 20060101ALI20220114BHEP

Ipc: A61L 31/14 20060101ALI20220114BHEP

Ipc: A61L 31/12 20060101ALI20220114BHEP

Ipc: A61L 31/04 20060101ALI20220114BHEP

Ipc: A61F 2/02 20060101AFI20220114BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230928

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240325